In these trials, data on renal outcomes were also collected (Table 1), although not all trials had this as a prespecified outcome, and therefore the data should be interpreted with caution
5C), indicating its protective effect in mitigating the impaired autophagic flux in the RTCs treated with PFOS

At a glance GLP-1 medications are changing how consumers eat, with appetite suppression, smaller portions and altered taste preferences driving demand for nutrient-dense, high-protein foods Brands can lead through smarter reformulation, offering products fortified with protein, fibre and clean label sweeteners to help consumers stay nourished on fewer calories Improving nutrient density can drive opportunity high-protein, high fibre, portion-controlled foods and beverages align with new consumer priorities for long-term weight and wellness management Innovation spans multiple categories, with bakery, snacks and beverages being ideal platforms for nutrient-dense reformulations that balance functionality, taste and texture Ingredion's portfolio of resistant starches, prebiotic fibres, pulse proteins and low- and no-calorie sweeteners help formulators meet the evolving nutritional needs of consumers on GLP-1 based medications as well as those looking to manage their weight without pharmaceuticals Weight management trends are redefining nutrition and pushing brands to reformulate For food and beverage brands, this shift represents far more than a dietary trend

And while it's true that increased NO production and higher carnitine levels can definitely increase your athletic performance, higher exercise intensity is probably not the main reason that GBB causes increased sweating
Among the 12% of adults who have ever taken GLP-1 drugs, most report taking them, at least in part, to treat a chronic condition like diabetes or heart disease, with fewer saying they took them only to lose weight